Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-11T20:19:17.028Z Has data issue: false hasContentIssue false

Levomilnacipran

Published online by Cambridge University Press:  19 October 2021

Stephen M. Stahl
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide
Stahl's Essential Psychopharmacology
 , pp. 403 - 408
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Auclair, AL, Martel, JC, Assié, MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013;70:338–47.CrossRefGoogle ScholarPubMed
Citrome, L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2013;67:1089–104.CrossRefGoogle ScholarPubMed
Mago, R, Forero, G, Greenberg, WM, Gommoll, C, Chen, C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig 2013;33:761–71.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Levomilnacipran
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.069
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Levomilnacipran
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.069
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Levomilnacipran
  • Stephen M. Stahl, University of California, San Diego
  • Book: Prescriber's Guide
  • Online publication: 19 October 2021
  • Chapter DOI: https://doi.org/10.1017/9781108921275.069
Available formats
×